Form 4: Heron CFO Converts RSUs to Common Stock

Heron Therapeutics CFO Ira Duarte converted 11,695 restricted stock units into common stock, correcting prior filing errors.

Summary

• Ira Duarte, EVP, Chief Financial Officer of Heron Therapeutics, Inc. (HRTX), converted 11,695 Restricted Stock Units (RSUs) into 11,695 shares of common stock on July 31, 2025.
• Following this transaction, Duarte directly beneficially owns 164,218 shares of common stock and 163,721 Restricted Stock Units.
• The filing corrects previous Form 4 filings (April 22, 2025, May 2, 2025, and June 17, 2025) where RSU dispositions were erroneously reported as acquisitions.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• The Restricted Stock Units vest in 16 equal installments, beginning one quarter after the grant date of January 31, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is primarily administrative, reporting a routine insider transaction (RSU conversion) and correcting prior errors. The correction of errors is a positive for transparency, but the transaction itself is expected and does not indicate new strategic direction or financial performance.

Positives

• The conversion of Restricted Stock Units into common stock represents a standard vesting event for executive compensation.
• The filing proactively corrects previous administrative errors in Form 4 disclosures, demonstrating transparency and adherence to reporting standards.

Negatives

• Previous Form 4 filings (April 22, 2025, May 2, 2025, and June 17, 2025) contained erroneous disclosures regarding RSU transactions, requiring this corrective filing.

Future Outlook

This Form 4 primarily reports an insider transaction and correction of prior administrative errors, and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The number of restricted stock units disclosed on the Reporting Person's Form 4 filed on April 22, 2025, May 2, 2025 and June 17, 2025 ("Affected Form 4 Filings") were erroneously disclosed as an acquisition in Column 5(A) when it should have been disclosed as a disposition in Column 5(D). All other information in the Affected Form 4 Filings is correct.

Industry Context

This filing is a routine insider transaction report (Form 4) and does not provide information directly related to broader industry trends or competitive landscape. It reflects standard executive compensation practices within the pharmaceutical or biotechnology sector, where equity awards like RSUs are common.

Comparison to Industry Standards

• This Form 4 details an insider's equity transaction, which is a standard disclosure requirement across all publicly traded companies.
• The conversion of Restricted Stock Units (RSUs) into common stock is a common practice for executive compensation in the biotechnology and pharmaceutical industries, similar to how executives at companies like Amgen or Gilead Sciences might vest and convert their equity awards.
• The correction of prior filing errors, while an administrative matter, aligns with regulatory expectations for accurate and timely disclosure, a standard upheld by all SEC-regulated entities.

Stakeholder Impact

• Shareholders: Provides transparency on executive equity ownership and compensation, confirming a standard vesting event.
• Employees: No direct impact beyond the executive involved.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Continued vesting of remaining Restricted Stock Units in 16 equal installments, starting one quarter after January 31, 2025.

Key Dates

Recommendation

This Form 4 filing is an administrative report detailing a routine insider equity transaction (RSU conversion) and the correction of prior filing errors. It does not contain new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The transaction is a standard part of executive compensation and does not signal a significant positive or negative shift in the company's fundamentals. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a buy or sell decision.

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Executive Compensation, Ira Duarte, SEC Filing